PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsBexarotene
Targretin(bexarotene)
Bexarotene, Targretin (bexarotene) is a small molecule pharmaceutical. Bexarotene was first approved as Targretin on 1999-12-29. It is used to treat t-cell lymphoma cutaneous in the USA. It has been approved in Europe to treat t-cell lymphoma cutaneous. The pharmaceutical is active against retinoic acid receptor RXR-gamma, retinoic acid receptor RXR-alpha, and retinoic acid receptor RXR-beta. In addition, it is known to target peroxisome proliferator-activated receptor gamma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
Trade Name
FDA
EMA
Bexarotene, Targretin (discontinued: Bexarotene)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bexarotene
Tradename
Company
Number
Date
Products
TARGRETINBausch Health CompaniesN-021056 RX2000-06-28
1 products, RLD, RS
TARGRETINBausch Health CompaniesN-021055 RX1999-12-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
bexaroteneANDA2024-11-27
targretinNew Drug Application2020-04-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
t-cell lymphoma cutaneous—D016410C84.A
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01X: Other antineoplastic agents in atc
— L01XF: Retinoids for cancer treatment
— L01XF03: Bexarotene
HCPCS
No data
Clinical
Clinical Trials
47 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LymphomaD008223—C85.9———1—1
T-cell lymphomaD016399—————1—1
T-cell lymphoma peripheralD016411—————1—1
T-cell lymphoma cutaneousD016410—C84.A———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBexarotene
INNbexarotene
Description
Bexarotene is a retinoid, a member of benzoic acids and a member of naphthalenes. It has a role as an antineoplastic agent.
Classification
Small molecule
Drug classarotinoid derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C
Identifiers
PDB—
CAS-ID153559-49-0
RxCUI—
ChEMBL IDCHEMBL1023
ChEBI ID50859
PubChem CID82146
DrugBankDB00307
UNII IDA61RXM4375 (ChemIDplus, GSRS)
Target
Agency Approved
RXRG
RXRG
RXRB
RXRB
Organism
Homo sapiens
Gene name
RXRG
Gene synonyms
NR2B3
NCBI Gene ID
6258
Protein name
retinoic acid receptor RXR-gamma
Protein synonyms
Nuclear receptor subfamily 2 group B member 3, Retinoid X receptor gamma
Uniprot ID
P48443
Mouse ortholog
Rxrg (20183)
retinoic acid receptor RXR-gamma (P28705)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,691 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bexarotene, Targretin
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,094 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use